Driven by "innovation + going global," the profitability of A-share biopharmaceutical companies is improving.

In the first half of 2026, the overall profitability of A-share biomedical companies improved significantly, achieving impressive results amidst resilient development. Innovation-driven growth and expansion into domestic and international markets became the core driving forces behind performance growth. As of August 3, 104 A-share biomedical companies had disclosed their performance for the first half of the year. From the lower limit of the projected net profit increase, 67 companies expect their net profit to grow. Additionally, 10 companies, including WuXi AppTec, Wuhua Pharmaceutical, and Zai Lab, disclosed their semi-annual reports, among which 7 achieved a year-on-year net profit increase or turned losses into profits.